Pimobendan

Inodilator Benzimidazole-pyridazinone derivative

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.25-0.3 mg/kg q12h Duration: Long-term (lifelong for heart failure)
Notes: Administer on an empty stomach (at least 1 hour before or 2 hours after feeding) to maximize absorption. For preclinical MMVD (Stage B2), use 0.25-0.3 mg/kg q12h.
Cat PO 0.25-0.3 mg/kg (or 1.25 mg/cat for typical weight) q12h Duration: Long-term
Notes: Off-label use. Monitor for adverse effects. Administer on an empty stomach if possible.
Horse PO 0.5 mg/kg q12h Duration: Variable; not well-established
Notes: Limited data; use with caution and under veterinary supervision.

Clinical Indications & Species Uses

General Indications
  • Heart failure management in small animals
Dog (Canine)
  • Congestive heart failure due to myxomatous mitral valve disease (MMVD)
  • Dilated cardiomyopathy (DCM)
  • Preclinical MMVD (Stage B2) to delay onset of CHF
Cat (Feline)
  • Hypertrophic cardiomyopathy (HCM) with congestive heart failure (off-label)
  • Restrictive cardiomyopathy (RCM) with congestive heart failure (off-label)
  • Dilated cardiomyopathy (DCM) (off-label)

Pharmacology & Mechanism of Action

Drug Class: Inodilator | Pharmacological Group: Benzimidazole-pyridazinone derivative

Mechanism of Action: Pimobendan is a positive inotropic and vasodilator agent (inodilator). Its primary mechanism of action is the sensitization of cardiac myofilaments to calcium, thereby increasing myocardial contractility without increasing intracellular calcium concentrations or myocardial oxygen demand. Additionally, it inhibits phosphodiesterase III (PDE3) in cardiac and vascular smooth muscle, leading to increased cyclic AMP levels, which results in positive inotropy and peripheral vasodilation. The combination of enhanced contractility and reduced afterload improves cardiac output and myocardial perfusion.

Pharmacodynamics: Pimobendan produces a dose-dependent increase in myocardial contractility, as evidenced by increased fractional shortening and cardiac output. It also reduces systemic vascular resistance and pulmonary capillary wedge pressure, improving hemodynamics in heart failure. In dogs with myxomatous mitral valve disease (MMVD), pimobendan delays the onset of congestive heart failure and improves survival. Its inotropic effect is more pronounced than that of digoxin, and its vasodilatory effect is comparable to that of ACE inhibitors.

⚡ Pharmacokinetics Summary

Absorption: Pimobendan is rapidly and well absorbed after oral administration. Peak plasma concentrations are reached within 1-2 hours in dogs. The active metabolite, O-desmethyl-pimobendan, also contributes to the pharmacological effects.
Distribution: Pimobendan is widely distributed in tissues. It is approximately 93% protein-bound in dogs. The volume of distribution is not well-defined but is likely moderate.
Metabolism: Pimobendan undergoes extensive hepatic metabolism, primarily via O-demethylation to form the active metabolite O-desmethyl-pimobendan. This metabolite is also pharmacologically active and contributes to the overall effect.
Excretion: Excretion is primarily via the biliary route into feces, with a smaller amount excreted in urine. In dogs, the elimination half-life of pimobendan is approximately 0.5-1 hour, while the active metabolite has a half-life of about 2 hours.
Half-Life: Dog: 0.5-1 hour (parent), 2 hours (active metabolite); Cat: approximately 1.5 hours (parent), 3 hours (metabolite); Horse: not well-established.
Bioavailability: Oral bioavailability is approximately 60-70% in dogs due to first-pass metabolism.
Protein Binding: Approximately 93% in dogs; similar in other species.

Available Formulations & Strengths

Oral Tablet 1.25 mg, 5 mg, 10 mg (PO)
Chewable Tablet 1.25 mg, 5 mg, 10 mg (PO)
Oral Suspension (compounded) Various (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to pimobendan or any component
  • Hypertrophic cardiomyopathy (HCM) with outflow obstruction (may worsen obstruction)
  • Concurrent use with other PDE inhibitors (e.g., sildenafil) due to additive vasodilation
  • Severe aortic stenosis or other fixed outflow obstructions
  • Pregnancy and lactation (safety not established)
Warnings & Clinical Precautions:
  • Use with caution in patients with hypotension, severe hepatic or renal impairment
  • Monitor for arrhythmias, especially in patients with pre-existing ventricular arrhythmias
  • In cats, use with caution in HCM with dynamic outflow tract obstruction
  • Do not use in animals with known hypersensitivity
  • May cause gastrointestinal upset; administer with food if vomiting occurs (though absorption may be reduced)
  • Use in food animals is prohibited in many countries due to lack of withdrawal times

Adverse Effects & Reactions

Common:

  • Vomiting
  • Diarrhea
  • Anorexia
  • Lethargy

Serious / Severe:

  • Arrhythmias (ventricular tachycardia, atrial fibrillation)
  • Hypotension
  • Syncope
  • Increased heart rate

Rare:

  • Hepatotoxicity
  • Thrombocytopenia
  • Allergic reactions

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
ACE inhibitors (e.g., enalapril, benazepril) Additive vasodilation and potential hypotension; monitor blood pressure. Moderate
Diuretics (e.g., furosemide) Additive hypovolemia and hypotension; monitor renal function and electrolytes. Moderate
Vasodilators (e.g., hydralazine, amlodipine) Severe hypotension may occur; use with caution. High
Beta-blockers (e.g., atenolol) May counteract positive inotropic effects; use with caution. Moderate
Digoxin Additive inotropic effects; monitor for toxicity. Moderate
Other PDE inhibitors (e.g., sildenafil) Additive vasodilation and risk of hypotension. High

Overdose & Toxicity Management

Signs of Toxicity:

  • Vomiting
  • Hypotension
  • Tachycardia
  • Arrhythmias
  • Lethargy
  • Collapse

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and animal is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids for hypotension, and use antiarrhythmics (e.g., lidocaine for ventricular arrhythmias) as needed. Monitor cardiac function and blood pressure closely. There is no specific antidote.

Food Animal Withdrawal Times

Not approved for use in food animals. Withdrawal times are not established. Do not use in animals intended for human consumption.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Keep in a dry place, protect from moisture. Keep out of reach of children and animals.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs (Vetmedin) by the FDA. Not approved for other species.

Extra-Label (Off-Label) Use: In the US, pimobendan is FDA-approved for dogs (Vetmedin). Extra-label use in other species is permitted under AMDUCA if a valid veterinarian-client-patient relationship exists, but must comply with withdrawal time requirements for food animals (none established).

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pimobendan is a cornerstone in the management of canine congestive heart failure, particularly due to MMVD and DCM. It has been shown to improve quality of life and survival. In cats, it is used off-label for heart failure, but its role is less established. Always combine with appropriate diuretic and ACE inhibitor therapy as needed. Monitor renal function, electrolytes, and cardiac status regularly. Administer on an empty stomach for optimal absorption. Adjust dose based on response and tolerability. In case of adverse effects, consider dose reduction or alternative therapy.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)